Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.30 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
| ▸ | INPP5B | P32019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192750 | 0.91 | FDPS (0.50) | FDPSBLMTDP1CA4 | |
| Pyrophosphoric Acid SCHEMBL28647299 | 0.81 | FDPS (0.77) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL503971 | 0.81 | FDPS (0.77) | FDPSBLMTDP1CA4BTN3A1 | |
| SCHEMBL27355305 | 0.79 | FDPS (0.41) | FDPSBLMTDP1CA4 | |
| SCHEMBL1576918 | 0.79 | — | — | |
| SCHEMBL3191083 | 0.79 | — | — | |
| Pyrophosphoric Acid SCHEMBL8416891 | 0.77 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL27805716 | 0.77 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL10770702 | 0.77 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110168080-B | Methods of detecting AAV | 建新公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118028318-A | Optimized CYP4V2 gene and application thereof | 苏州诺洁贝生物技术有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111356763-B | Variant RNAi | 建新公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-115896135-B | Optimized PAH gene and expression cassette and use thereof | 苏州诺洁贝生物技术有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117460832-A | Size exclusion chromatography of empty AAV capsids and intact AAV capsids | 建新公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-114381465-B | Optimized CYP4V2 gene and application thereof | 苏州诺洁贝生物技术有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117085113-A | TMEM25 protein and application thereof in cancer treatment | 厦门大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-116940372-A | Haemophilus influenzae vaccine and methods of use | 罗切斯特综合医院 | 2023-10-24 | — | — | CN | disclosed |
| CN-116801719-A | Formulations for cryopreservation of PBMC | SQZ生物技术公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116648503-A | Human PAH expression cassettes for treatment of PKU by liver-directed gene replacement therapy | 建新公司 | 2023-08-25 | — | — | CN | disclosed |
| US-6030813-A | CHAIN EXTENSION BY ANNEALING PRIMER CONTAINING N3'-PHOSPHORAMIDATE AND PHOSPHODIESTER LINKAGES TO A POLYNUCLEOTIDE TEMPATE, THEN JOINING A NUCLEOTIDE TO THE PRIMER BY A POLYMERASE CATALYZED REACTION | THE PERKIN-ELMAR CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| US-5965720-A | WITH SEQUENCE COMPLEMENTARY TO MESSENGER RNA FROM A GENE SELECTED FROM THE GROUP CONSISTING OF C-MYC, C-MYB, C-FOS, C-KIT, RAS AND BCR/ABL; ANTISENSE/ANTICARCINOGENIC AGENTS | LYNX THERAPEUTICS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5837835-A | STABILITY; HEAT RESISTANCE | LYNX THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5726297-A | Oligodeoxyribonucleotide N3' P5' phosphoramidates | LYNX THERAPEUTICS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5631135-A | HYBRIDIZATION OF RIBONUCLEIC ACID TARGET; GENETIC ENGINEERING | LYNX THERAPEUTICS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5599922-A | INHIBITOR TO SNAKE VENON PHOSPHODIESTERASE | LYNX THERAPEUTICS, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5591607-A | Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation | LYNX THERAPEUTICS, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |